BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 89 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,452,220 | +14172.4% | 506,000 | -74.9% | 0.08% | -83.7% |
Q2 2023 | $10,175 | +167.2% | 2,014,858 | 0.0% | 0.47% | +152.4% |
Q1 2023 | $3,808 | -99.9% | 2,014,858 | 0.0% | 0.19% | -2.1% |
Q4 2022 | $3,626,744 | +6.5% | 2,014,858 | 0.0% | 0.19% | 0.0% |
Q3 2022 | $3,405,000 | -31.3% | 2,014,858 | 0.0% | 0.19% | -39.2% |
Q2 2022 | $4,957,000 | -11.2% | 2,014,858 | 0.0% | 0.31% | +9.4% |
Q1 2022 | $5,581,000 | -48.0% | 2,014,858 | 0.0% | 0.29% | -31.2% |
Q4 2021 | $10,739,000 | -37.0% | 2,014,858 | 0.0% | 0.42% | -29.9% |
Q3 2021 | $17,046,000 | -30.6% | 2,014,858 | 0.0% | 0.60% | -31.4% |
Q2 2021 | $24,561,000 | -49.8% | 2,014,858 | 0.0% | 0.87% | -47.7% |
Q1 2021 | $48,880,000 | -24.3% | 2,014,858 | 0.0% | 1.66% | -20.1% |
Q4 2020 | $64,576,000 | +6.0% | 2,014,858 | 0.0% | 2.08% | -1.4% |
Q3 2020 | $60,909,000 | -28.3% | 2,014,858 | 0.0% | 2.10% | -43.6% |
Q2 2020 | $84,946,000 | +69.0% | 2,014,858 | 0.0% | 3.74% | +9.0% |
Q1 2020 | $50,271,000 | – | 2,014,858 | – | 3.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |